MX9603489A - Peptidos opiodes novedosos para el tratamiento del dolor y uso de los mismos. - Google Patents
Peptidos opiodes novedosos para el tratamiento del dolor y uso de los mismos.Info
- Publication number
- MX9603489A MX9603489A MX9603489A MX9603489A MX9603489A MX 9603489 A MX9603489 A MX 9603489A MX 9603489 A MX9603489 A MX 9603489A MX 9603489 A MX9603489 A MX 9603489A MX 9603489 A MX9603489 A MX 9603489A
- Authority
- MX
- Mexico
- Prior art keywords
- peptides
- pain
- treatment
- opioid
- opioid peptides
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Esta invencion se relaciona con una serie de péptidos opioides novedosos para el tratamiento del dolor y composiciones farmacéuticamente aceptables constituidas por estos péptidos. La invencion también describe métodos para controlar el dolor en pacientes mediante la utilizacion de las composiciones de la invencion. Los péptidos de esta invencion tienen un alto grado de selectividad por el receptor æ-opiode. Estos péptidos son altamente lipofílicos. Pese a su carácter lipofílico no atraviesan con facilidad la barrera hematoencefálica (BBB). Los péptidos de la presente invencion son particularmente adecuados como agentes analgésicos que actuan sustancialmente sobre los receptores æ-opioides periféricos. Debido a que estos péptidos actuan de manera periférica, sustancialmente evitan la produccion de efectos colaterales normalmente asociados con la accion analgésica central.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9403263A GB9403263D0 (en) | 1994-02-21 | 1994-02-21 | Novel opiod peptides |
GB9408179A GB9408179D0 (en) | 1994-02-21 | 1994-04-25 | Novel opioid peptides for the treatment of pain and use thereof |
SE9401519A SE9401519D0 (sv) | 1994-05-03 | 1994-05-03 | Novel opioid peptides for the tratment of pain and use thereof |
PCT/SE1995/000158 WO1995022557A1 (en) | 1994-02-21 | 1995-02-15 | Novel opioid peptides for the treatment of pain and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX9603489A true MX9603489A (es) | 1997-03-29 |
Family
ID=27267061
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX9603489A MX9603489A (es) | 1994-02-21 | 1995-02-15 | Peptidos opiodes novedosos para el tratamiento del dolor y uso de los mismos. |
Country Status (20)
Country | Link |
---|---|
EP (1) | EP0746567B1 (es) |
JP (1) | JPH09509168A (es) |
AT (1) | ATE217011T1 (es) |
BR (1) | BR9506847A (es) |
CA (1) | CA2181367A1 (es) |
CZ (1) | CZ288523B6 (es) |
DE (1) | DE69526577T2 (es) |
EE (1) | EE03265B1 (es) |
ES (1) | ES2176322T3 (es) |
FI (1) | FI963252A0 (es) |
HR (1) | HRP950413A2 (es) |
HU (1) | HUT74731A (es) |
IS (1) | IS4261A (es) |
MX (1) | MX9603489A (es) |
NO (1) | NO963464L (es) |
NZ (1) | NZ281742A (es) |
PL (1) | PL181092B1 (es) |
SK (1) | SK93596A3 (es) |
TW (1) | TW408131B (es) |
WO (1) | WO1995022557A1 (es) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9503924D0 (sv) * | 1995-08-18 | 1995-11-07 | Astra Ab | Novel opioid peptides |
EP0853484B1 (en) * | 1995-06-07 | 2002-09-11 | Torrey Pines Institute For Molecular Studies | Novel mu opioid receptor ligands: agonists and antagonists |
GB9516994D0 (en) * | 1995-08-18 | 1995-10-18 | Iaf Biochem Int | Solution synthesis of peripheral acting analgestic opioid tetrapeptides |
MX9709494A (es) * | 1996-12-04 | 1998-07-31 | Pfizer | Compuestos peptidicos ciclicos, procedimiento para su produccion, composiciones que los contienen y uso de los mismos. |
US5885958A (en) * | 1997-03-25 | 1999-03-23 | Administrators Of The Tulane Educational Fund | Mu-opiate receptor peptides |
US6548637B1 (en) | 1998-06-18 | 2003-04-15 | Sepracor, Inc. | Ligands for opioid receptors |
SE9900961D0 (sv) | 1999-03-16 | 1999-03-16 | Astra Ab | Novel compounds |
US7115664B2 (en) | 2000-03-16 | 2006-10-03 | Sepracor Inc. | Peptidomimetic ligands for cellular receptors and ion channels |
EP1303186B1 (en) | 2000-07-18 | 2011-01-26 | Cornell Research Foundation, Inc. | Medicinal uses of mu-opioid receptor agonists |
EP2491943B1 (en) | 2003-02-04 | 2018-10-10 | Cornell Research Foundation, Inc. | Methods for preventing mitochondrial permeability transition |
EP3167935B1 (en) | 2003-05-01 | 2018-07-18 | Cornell Research Foundation, Inc. | Method and carrier complexes for delivering molecules to cells |
RU2376028C2 (ru) | 2004-01-23 | 2009-12-20 | Корнелл Рисеч Фаундейшн, Инк. | Способ уменьшения окислительного повреждения (варианты) |
EP1879567A1 (en) | 2005-04-28 | 2008-01-23 | Pfizer Limited | Amino acid derivatives |
CA2622911C (en) | 2005-09-16 | 2016-12-06 | Cornell Research Foundation, Inc. | Methods for reducing cd36 expression |
EP1782819A1 (en) | 2005-11-03 | 2007-05-09 | Cognis IP Management GmbH | Oligopeptides and their use |
WO2008057608A2 (en) | 2006-11-10 | 2008-05-15 | Cara Therapeutics, Inc. | Synthetic peptide amides |
US7842662B2 (en) | 2006-11-10 | 2010-11-30 | Cara Therapeutics, Inc. | Synthetic peptide amide dimers |
US8236766B2 (en) | 2006-11-10 | 2012-08-07 | Cara Therapeutics, Inc. | Uses of synthetic peptide amides |
US8906859B2 (en) | 2006-11-10 | 2014-12-09 | Cera Therapeutics, Inc. | Uses of kappa opioid synthetic peptide amides |
US7713937B2 (en) | 2006-11-10 | 2010-05-11 | Cara Therapeutics, Inc. | Synthetic peptide amides and dimeric forms thereof |
CN102127152B (zh) * | 2007-06-11 | 2012-07-04 | 北京大学 | 一种抗阿片肽的拮抗肽与该拮抗肽的应用 |
CN102127151B (zh) * | 2007-06-11 | 2012-07-04 | 北京大学 | 抗阿片肽的拮抗肽与该拮抗肽的应用 |
CN101805396B (zh) * | 2007-06-28 | 2011-09-14 | 北京大学 | 抗阿片肽的拮抗肽与该拮抗肽的应用 |
CN101817877B (zh) * | 2007-06-28 | 2011-09-14 | 北京大学 | 一种抗阿片肽的活性片段 |
ES2458870T3 (es) | 2008-02-07 | 2014-05-07 | Cornell University | Procedimientos para prevenir o tratar la resistencia a la insulina |
EP3741381B1 (en) | 2008-02-26 | 2024-04-24 | Cornell University | A peptide for use for prevention and treatment of acute renal injury |
CN112469729A (zh) * | 2018-05-31 | 2021-03-09 | 悉尼大学 | 镇痛剂及其使用方法 |
JP7437578B2 (ja) * | 2019-03-20 | 2024-02-26 | 国立大学法人東北大学 | 新規オピオイドペプチド、その糖鎖付加体及びそれらを含む医薬組成物 |
CN113968902B (zh) * | 2020-07-25 | 2023-05-26 | 兰州大学 | 亮氨酸-脑啡肽类似物及其制备方法和应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL8005121A (nl) * | 1979-09-20 | 1981-03-24 | Erba Farmitalia | Biologisch actieve peptiden. |
CZ168194A3 (en) * | 1992-11-12 | 1994-12-15 | Biomeasure | Opioid peptides |
SE9300012D0 (sv) * | 1993-01-05 | 1993-01-05 | Astra Ab | New peptides |
-
1995
- 1995-02-13 IS IS4261A patent/IS4261A/is unknown
- 1995-02-15 HU HU9602281A patent/HUT74731A/hu unknown
- 1995-02-15 CA CA002181367A patent/CA2181367A1/en not_active Abandoned
- 1995-02-15 JP JP7521753A patent/JPH09509168A/ja not_active Abandoned
- 1995-02-15 ES ES95910838T patent/ES2176322T3/es not_active Expired - Lifetime
- 1995-02-15 DE DE69526577T patent/DE69526577T2/de not_active Expired - Fee Related
- 1995-02-15 MX MX9603489A patent/MX9603489A/es unknown
- 1995-02-15 EP EP95910838A patent/EP0746567B1/en not_active Expired - Lifetime
- 1995-02-15 WO PCT/SE1995/000158 patent/WO1995022557A1/en active IP Right Grant
- 1995-02-15 PL PL95315947A patent/PL181092B1/pl unknown
- 1995-02-15 AT AT95910838T patent/ATE217011T1/de not_active IP Right Cessation
- 1995-02-15 BR BR9506847A patent/BR9506847A/pt not_active Application Discontinuation
- 1995-02-15 EE EE9600071A patent/EE03265B1/xx not_active IP Right Cessation
- 1995-02-15 SK SK935-96A patent/SK93596A3/sk unknown
- 1995-02-15 CZ CZ19962391A patent/CZ288523B6/cs not_active IP Right Cessation
- 1995-02-15 NZ NZ281742A patent/NZ281742A/en unknown
- 1995-02-16 TW TW084101429A patent/TW408131B/zh not_active IP Right Cessation
- 1995-07-19 HR HR9401519-5A patent/HRP950413A2/hr not_active Application Discontinuation
-
1996
- 1996-08-20 FI FI963252A patent/FI963252A0/fi unknown
- 1996-08-20 NO NO963464A patent/NO963464L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO1995022557A1 (en) | 1995-08-24 |
EE03265B1 (et) | 2000-04-17 |
PL181092B1 (pl) | 2001-05-31 |
PL315947A1 (en) | 1996-12-09 |
ATE217011T1 (de) | 2002-05-15 |
TW408131B (en) | 2000-10-11 |
DE69526577D1 (de) | 2002-06-06 |
BR9506847A (pt) | 1997-09-30 |
AU1865195A (en) | 1995-09-04 |
HUT74731A (en) | 1997-02-28 |
HRP950413A2 (en) | 1997-10-31 |
JPH09509168A (ja) | 1997-09-16 |
NZ281742A (en) | 1997-06-24 |
CZ288523B6 (cs) | 2001-07-11 |
EP0746567B1 (en) | 2002-05-02 |
FI963252A (fi) | 1996-08-20 |
DE69526577T2 (de) | 2003-01-02 |
HU9602281D0 (en) | 1996-10-28 |
SK93596A3 (en) | 1997-05-07 |
CZ239196A3 (en) | 1996-12-11 |
EP0746567A1 (en) | 1996-12-11 |
AU690648B2 (en) | 1998-04-30 |
IS4261A (is) | 1995-08-22 |
CA2181367A1 (en) | 1995-08-24 |
ES2176322T3 (es) | 2002-12-01 |
FI963252A0 (fi) | 1996-08-20 |
NO963464L (no) | 1996-08-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX9603489A (es) | Peptidos opiodes novedosos para el tratamiento del dolor y uso de los mismos. | |
SE9503924D0 (sv) | Novel opioid peptides | |
AU2002225772A1 (en) | Therapeutic agents and methods of use thereof for treating an amyloidogenic disease | |
IL97446A0 (en) | Enhancement of the down-regulation of autoimmune diseases by oral administration of autoantigens | |
GR3022459T3 (en) | Quinuclidine derivative as substance p antagonist. | |
DE60134453D1 (de) | Pharmazeutische Zusammensetzungen zur Behandlung von ZNS und anderen Krankheiten | |
MY137348A (en) | Highly selective norepinephrine reuptake inhibitors and methods of using the same | |
EP0552256A4 (es) | ||
CA2054822A1 (en) | Formulations and their use in the treatment of neurological diseases | |
IL147852A0 (en) | Chemokine receptor antagonists and pharmaceutical compositions containing the same | |
ZA952086B (en) | Heterocyclic compounds their preparation and use | |
CA2143610A1 (en) | Use of norastemizole for the treatment of allergic disorders | |
IL118833A (en) | Sertraline for use as a medicament in the treatment of post-myocardial infarction patients | |
EP1164141A3 (en) | Opioid peptides and their use for treatment of pain | |
MX9801192A (es) | Nuevos peptidos opioides. | |
YU24603A (sh) | Novi farmaceutski preparati koji sadrže epinastin i pseudoefedrin | |
CA2135752A1 (en) | Use of (E)-2-(p-Fluorophenethyl)-3-Fluoroallylamine in the Treatment of Alzheimer's Disease | |
UA22223A (uk) | Спосіб лікуваhhя захворюваhь оргаhа зору | |
RU97112616A (ru) | Лекарственный препарат для лечения проктологических заболеваний | |
CA2532330A1 (en) | Highly selective norepinephrine reuptake inhibitors and methods of using the same |